UBS Group Analysts Give Symrise (SY1) a €82.00 Price Target

Share on StockTwits

UBS Group set a €82.00 ($95.35) price objective on Symrise (FRA:SY1) in a research report report published on Wednesday, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the stock.

Several other analysts have also issued reports on the stock. Sanford C. Bernstein set a €73.00 ($84.88) price target on shares of Symrise and gave the stock a neutral rating in a research report on Wednesday. Credit Suisse Group set a €84.00 ($97.67) price target on shares of Symrise and gave the stock a buy rating in a research report on Wednesday. Nord/LB set a €74.00 ($86.05) price target on shares of Symrise and gave the stock a neutral rating in a research report on Wednesday. Baader Bank set a €82.50 ($95.93) price target on shares of Symrise and gave the stock a buy rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. set a €77.00 ($89.53) price target on shares of Symrise and gave the stock a neutral rating in a research report on Wednesday. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have given a buy rating to the company’s stock. Symrise presently has a consensus rating of Hold and an average price target of €74.09 ($86.15).

FRA SY1 opened at €72.02 ($83.74) on Wednesday. Symrise has a 1 year low of €56.96 ($66.23) and a 1 year high of €73.48 ($85.44).

Symrise Company Profile

Symrise AG develops, produces, and sells fragrances, flavorings, and cosmetic ingredients. It operates through three segments: Scent & Care, Flavor, and Nutrition. The Scent & Care segment develops, produces, and sells fragrance ingredients and compositions, cosmetic ingredients, and mint flours, as well as specific application processes for such substances.

Featured Story: Hedge Funds – Risk or Reward?

Analyst Recommendations for Symrise (FRA:SY1)

Receive News & Ratings for Symrise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symrise and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.